Ozempic is the injectable peptide GLP-1 medicine with the most FDA-approved uses in type 2 diabetes, with indications to improve blood sugar along with diet and exercise, to reduce the risk of major cardiovascular events (heart attack, stroke, or death) in adults who also have known heart disease, and to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults who also have chronic kidney disease
This triple mechanism distinguishes it from dual-agonist peptides like tirzepatide (GLP-1/GIP) and single-agonist compounds like semaglutide (GLP-1 only), making it the most broadly acting incretin-class compound currently under clinical investigation
Other publications discussed: user-friendly intuitive eCOA design, flexible data collection and monitoring methods, patient-centered protocol design, and comprehensive participant and site training
Enlarged right superior temporal gyrus in children and adolescents with autism
(2z,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic Acid 184